Tumor Markers
Tumor Marker: a biomarker found in the body system that can be elevated by the presence of all types of cancer. Each tumor marker is indicative of a particular disease process, and are used in oncology to help detect the presence of cancer.
MAR 24, 2021
7:00 AM PDT
MAR 24, 2021
7:00 AM PDT
Date: March 24, 2021 Time: 7:00am (PST), 10:00am (EST), 3:00pm (CET) Multiplex immunofluorescence IHC is a powerful technique to address the increasing research needs in immuno-oncology t...
MAR 09, 2021
8:00 AM PST
MAR 09, 2021
8:00 AM PST
Date: March 09, 2021 Time: 8:00am (PST), 11:00am (EST) Lung cancer is one of the three most common types of cancer. Representing 85% of all lung cancers...
JAN 28, 2021
7:00 AM PST
C.E. CREDITS
JAN 28, 2021
7:00 AM PST
Date: January 28, 2021 Time: 7:00am (PST), 10:00am (EST) Many of the newly recognized clinically significant genetic markers in pediatric leukemias cannot be reliably detected by routine dia...
NOV 13, 2020
4:00 PM PST
NOV 13, 2020
4:00 PM PST
Three-dimensional (3D) cell culture spheroids and aggregates are preferred over monolayer cell culture due to their architectural and functional similarity to solid tumors. To study expressi...
NOV 12, 2020
9:00 AM PST
NOV 12, 2020
9:00 AM PST
Three-dimensional (3D) cell culture spheroids and aggregates are preferred over monolayer cell culture due to their architectural and functional similarity to solid tumors. To study expressi...
NOV 12, 2020
C.E. CREDITS
NOV 12, 2020
Cancer cells can acquire immune resistance resulting in a loss of immunosurveillance. Tumor cells can upregulate PDL-1 which binds to PD-1. This complex inhibits CD8 Tumor Infiltrating cells...
C.E. CREDITS
Dr. Bacher will be discussing the history and evolution of MSI, the differences between popular testing methods, and what the future holds for this powerful biomarker....
OCT 22, 2020
4:40 PM CEST
C.E. CREDITS
OCT 22, 2020
4:40 PM CEST
Identification of actionable mutations, determination of tumor mutational burden (TMB) and microsatellite (MS) status are paramount to precision oncology and the Oncomine Comprehensive Assay...
OCT 22, 2020
4:40 PM CEST
OCT 22, 2020
4:40 PM CEST
IIdentification of relevant mutations, determination of tumor mutational burden (TMB) and microsatellite (MS) status are paramount to precision oncology research and the Oncomine Comprehensi...
OCT 22, 2020
4:20 PM CEST
C.E. CREDITS
OCT 22, 2020
4:20 PM CEST
During the presentation, Dr. Hernandez-Losa will describe the experience in the Department of Pathology using NGS with S5-xl in different translational projects in solid tumors. Additionally...
